On the other hand, a concomitant modification in these parameters was noticed proceeding cisplatin, TiNPs-cisplatin and lactoferrin-cisplatin, Doxorubicin, TiNPs-doxorubicin, Lactoferrin-doxorubicin and Neupogen treatment with the lactoferrin-cisplatin and lactoferrin-doxorubicin elucidating the highest significant impact by about 0.89 and 0.98 folds, respectively, highlighting the impact of these genes mutation in T-ALL (Figure 4). This evidence concerns the gene LTF and acute lymphoblastic leukemia.